All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Kyle Mitchell, MD, MSc

Elliot Servais, MD
Disclosure(s): Intuitive Surgical Inc.: Consultant (Ongoing)

Presentations

1.     Synchronous Primary Stage I Non-Small Cell Lung Cancer: Trends in Management and Survival
   Nikki E. Rossetti, MD, MS
    
2. Not All T4 Patients Should Be Considered Equal: NSCLC Heterogeneity and Surgical Outcome
   Xun Luo, MD, MPH
    
3. Reassessing Perioperative Risks: Impact of Neoadjuvant Therapy on Mortality in Pneumonectomy
   Christina S. Boutros, DO
    
4. Delayed Surgery Decreases Overall Survival in Early-Stage Non-Small Cell Lung Cancer: A Propensity Matched Cohort Analysis
   Alyssa Murillo, MD, MS, MA.Ed
   Disclosure(s): DaVinci Intuitive Surgical: Recipient of UCSF Intuitive Surgical Simulation Based Fellowship (Ongoing)
    
5. Utilization and Survival Outcomes of Surgical Resection for Clinical Stage IIIB Non-Small Cell Lung Cancer
   Ryan C. Jacobs, MD, MS
    
6. Social Vulnerability Index Is Associated with Time-to-Treatment in Resectable Non-Small Cell Lung Cancer
   Arsalan A. Khan, MD
    
7. Clinical Stage II Non-Small Cell Lung Cancer: Can We “Just Give Adjuvant Therapy”?
   Rajika Jindani, MD, MPH
    
8. Debate: No—Neoadjuvant Therapy for Node-Negative NSCLC
   Raja Flores, MD
    
9. Debate: Yes—Neoadjuvant Therapy for Node-Negative NSCLC
   Nathaniel R. Evans, III, MD
   Disclosure(s): Astra Zeneca: Advisory Board (Ongoing); Bristol Myers Squib: Advisory Board (Ongoing); Intuitive Surgical: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Merck: Advisory Board (Ongoing), Speaker (Ongoing)
    
10. Discussion